Earlier this month, the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology for B-cell Lymphomas to include Yescarta for 'Relapsed disease
(C) 2022 Electronic News Publishing, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64.78 USD | -0.84% | -0.75% | -20.03% |
02/05 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
01/05 | Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75 | MT |
Earlier this month, the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology for B-cell Lymphomas to include Yescarta for 'Relapsed disease
(C) 2022 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
-20.03% | 81.46B | |
+26.08% | 681B | |
+21.85% | 556B | |
-4.77% | 361B | |
+16.97% | 325B | |
+5.69% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-3.40% | 157B |